Low price medicine spring? Ceiling of daily average fee will be cancelled

[pharmaceutical network industry trends 】According to media reports, in a reply to proposal 0177 of the second session of the 13th National Committee of the Chinese people's Political Consultative Conference recently, the state health insurance bureau made it clear: in the future, it will cancel the upper limit of the current daily average cost of low-cost drugs, establish a monitoring and early warning platform for the use of drugs in short supply as soon as possible, strengthen the production of fixed-point orders for clinical essential drugs, and form a joint force of low-cost drug price supervision Photo source: pharmaceutical network, the industry began to exclaim: the spring of low-cost medicine! But is that really the case? In fact, in recent years, many policies to support low-cost drugs have been introduced For example, the establishment of the normal reserve mechanism of short drugs, the development of dynamic monitoring of short drugs, the massive release of low-cost short drugs information in the national drug supply guarantee integrated management information platform, and the adoption of fixed-point production and centralized supply of some low-cost drugs all play a certain role in ensuring the supply of low-cost drugs However, while supporting low-cost drugs, in fact, there are certain restrictions attached For example, only when the daily average cost of Western medicine does not exceed 3 yuan, and the daily average cost of Chinese patent medicine does not exceed 5 yuan, can the enterprise price independently This situation has caused some pharmaceutical enterprises in raw materials, labor and other costs rise, the profit space is becoming smaller and smaller, seriously hit the enthusiasm of low-cost drug production As a result, in recent years, there has been a frequent shortage of low-cost drugs Therefore, the reply of the state health insurance bureau is undoubtedly to push forward the reform policy of low-cost drugs in short supply It is generally believed that the removal of the upper limit of the daily average cost of low-cost drugs will enable relevant enterprises to obtain reasonable profits and effectively alleviate the problem of drug shortage In fact, it can be seen from the newly issued opinions that the removal of the upper limit of the daily average cost of low-cost drugs is not only an inevitable trend of the current situation, but also a kind of trust of the state in the self-regulation of the market But at the same time, some people in the industry said that at present, the market competition has sufficient volume procurement and insufficient online price support In fact, low-cost drugs are not very important in terms of connotation This view will appear because in the new situation, the drug management is jointly controlled by the market and the administration If the price is low, it will be raised upward If the price is high, it will be pressed downward Establishing a monitoring and early warning mechanism for abnormal changes in price supply can not only prevent price hikes, but also prevent prices from being suppressed too low, resulting in the inability to supply Therefore, from this point of view, even if the upper limit of the daily average cost of low-cost drugs is released, enterprises can not adjust their prices freely And without the identity support of low-cost drugs, it means that the original low-cost drugs will participate in the flood of competition with most varieties in volume procurement, such as cataloguing, qualification, price and market So, it's really a question mark to see how much the cancellation of the daily average cost can promote the low-cost drugs On the whole, the reply of the state health insurance bureau is to cancel the upper limit of the current daily average cost of low-cost drugs, mainly for the purpose of enabling pharmaceutical enterprises to obtain reasonable profits, so as to effectively alleviate the problem of short-term or even long-term shutdown and supply interruption of drugs, and avoid low-cost drugs becoming drugs in short supply But what will be the result of low-cost drugs? We need to wait until the formal policy is issued and implemented During this period, pharmaceutical enterprises should keep rational cognition and judgment, and do not invest blindly.